Effectiveness and Safety of Anti-interleukin-17 Therapies in Elderly Patients with Psoriasis

• Main Authors: Céline Phan (Author), Nathalie Beneton (Author), Juliette Delaunay (Author), Ziad Reguiai (Author), Claire Boulard (Author), Anne-Claire Fougerousse (Author), Elisa Cinotti (Author), Marco Romanelli (Author), Laure Mery-Bossard (Author), Domitille Thomas-Beaulieu (Author), Josiane Parier (Author), François Maccari (Author), Jean-Luc Perrot (Author), Mireille Ruer-Mulard (Author), Marie Bastien (Author), Edouard Begon (Author), Mahtab Samimi (Author), Caroline Jacobzone (Author), Nathalie Quiles-Tsimaratos (Author), Vincent Descamps (Author), Maud Steff (Author), Paul Bilan (Author), Annie Vermersch-Langlin (Author), Mathilde Kemula (Author), Emmanuelle Amazan (Author), Ingrid Kupfer-Bessaguet (Author), Anne-Caroline Cottencin (Author), Francesca Prignano (Author), Bulai Livideanu (Author), Jeremy Gottlieb (Author), Alain Beauchet (Author), Emmanuel Mahé (Author)
• Format: Book
• Published: Medical Journals Sweden, 2020-11-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Summary

Anti-interleukin-17 agents have recently been developed for the treatment of psoriasis. This study evaluated the tolerance and effectiveness of anti-interleukin-17 agents for psoriasis in elderly patients in daily practice. A multicentre, retrospective study was performed, involving psoriatic patients aged ≥65 years who had received an anti-interleukin-17 agent, including secukinumab, ixekizumab or brodalumab. A total of 114 patients were included: 72 received secukinumab, 35 ixekizumab, and 7 brodalumab. Treatment was stopped in 32 patients (28.9%), because of relapses in 14 patients (41.2%), primary failures in 11 patients (32.4%), or adverse events in 7 patients (20.6%). The 3 most frequently reported adverse events were injection site reactions (n = 4), oral candidiasis (n = 3), and influenza-like illness (n = 3). Regarding effectiveness, 80 patients (70%) reached a Physician Global Assessment score of 0/1, 6 months after treatment initiation. In conclusion, anti-interleukin-17 therapy appears to be an effective and safe therapeutic option for psoriasis treatment in patients aged ≥ 65 years.

Item Description

0001-5555
1651-2057
10.2340/00015555-3678